Table I.
Patient characteristics.
| Characteristics | Number (%), n=14 | cfDNA ng/µl (95% CI) baseline, median |
|---|---|---|
| Sex | ||
| Male | 8 (57) | 1.15 (1.04–1.37) |
| Female | 6 (43) | 0.78 (0.64–1.11) |
| Age (years) | ||
| Median | 66 | |
| Range | 43–74 | |
| T stage | ||
| T1 | 0 (0) | |
| T2 | 0 (0) | |
| T3 | 4 (29) | 1.15 (1.13–1.16) |
| T4 | 8 (57) | 0.99 (0.65–1.30) |
| TX | 2 (14) | 0.97 (0.8–1.13) |
| N stage | ||
| N0 | 1 (7) | 1.01 (1.01–1.01) |
| N1 | 3 (21) | 1.13 (0.75–1.43) |
| N2 | 4 (29) | 1.06 (0.64–1.24) |
| NX | 6 (43) | 1.11 (0.65–1.15) |
| Site of primary | ||
| Colon | 9 (64) | 1.10 (0.75–1.23) |
| Rectal | 5 (36) | 1.07 (0.65–1.16) |
| Number of livermets (baseline) | ||
| Median | 10 | |
| Range | 1–60 | |
| Size of largest livermet (baseline, cm) | ||
| Median (95% CI) | 55 (39–92) | |
| Range (cm) | 2.5–18 | |
| RAS/BRAF mutation | ||
| Mutation | 4 | 0.88 (0.64–1.15) |
| Wild-type | 9 | 1.13 (0.86–1.30) |
| Unknown | 1 | 0.8 |
| Dose irinotecan (mg) | ||
| Median (95% CI) | 345 (243–395) | |
| Debut of metastases | ||
| Synchronous | 3 (21) | 1.16 (1.01–1.43) |
| Metachronous | 11 (79) | 1.03 (0.68–1.14) |
| Number of embolization | ||
| Median | 4 | |
| Range | 1–4 | |
T, T-stage of primary; N, N-stage of primary; CI, confidence interval; cfDNA, cell free DNA; RAS/BRAF, RAS/BRAF oncogene status in archival tissue.